Ciprofibrate is a lipid-lowering medication developed in the 1980s as part of the fibrate class of drugs used to treat abnormal blood lipid levels. It was introduced after researchers identified compounds that could reduce elevated triglycerides and improve cholesterol balance in patients at risk of cardiovascular disease. The drug belongs to a group that includes other fibrates designed to manage dyslipidemia.

BRAND NAMES

  • Lipanor – the most widely recognized and historically common brand (marketed by Sanofi in several countries) 
  • Modalim – used in some regions as an alternative branding

MECHANISM OF ACTION

Ciprofibrate works by activating the nuclear receptor PPAR-α (peroxisome proliferator-activated receptor alpha), which regulates lipid metabolism in the liver. This activation increases the breakdown of triglyceride-rich lipoproteins by enhancing lipoprotein lipase activity, reduces hepatic production of VLDL, and promotes fatty acid oxidation.

PHARMACOKINETICS

Absorption

Ciprofibrate is well absorbed after oral administration. It is rapidly and almost completely absorbed from the gastrointestinal tract, with peak plasma concentrations typically occurring within 1–4 hours.

Distribution

Ciprofibrate is highly bound to plasma proteins (about 95–99%), mainly albumin. It has a relatively small apparent volume of distribution, indicating that it remains largely within the vascular compartment rather than extensively distributing into tissues.

Metabolism

Ciprofibrate is primarily metabolized in the liver through phase II reactions, especially glucuronidation. It undergoes limited oxidative metabolism and does not significantly involve cytochrome P450 enzymes. The metabolites formed are mostly inactive and are excreted mainly via the kidneys.

Excretion

Ciprofibrate is eliminated mainly through the kidneys as unchanged drug and metabolites, with a smaller portion excreted in feces via bile. It has a relatively long elimination half-life, allowing once-daily dosing in most cases.

PHARMACODYNAMICS

Ciprofibrate pharmacodynamics are centered on activation of PPAR-α receptors, which regulate genes involved in lipid metabolism. This leads to increased lipoprotein lipase activity, enhanced fatty acid oxidation, reduced hepatic triglyceride synthesis, and decreased VLDL production. The overall effect is a significant reduction in plasma triglycerides and a moderate increase in HDL cholesterol, with only a mild effect on LDL levels.

ADMINISTRATION

Ciprofibrate is administered orally, usually in tablet form, once daily. It is recommended to take it at the same time each day, with or without food, as food does not significantly affect its absorption. Dosage is adjusted based on lipid levels and patient response.

DOSAGE AND STRENGTH

Ciprofibrate is a medicine used to lower high cholesterol and triglyceride levels in the blood. It is commonly available in a strength of 100 mg per tablet. The usual dosage for adults is 100 mg once daily, taken as prescribed by a doctor, often after food. The exact dosage may vary depending on the patient’s condition and response to treatment. Regular medical check-ups are important while using this medicine to ensure safety and effectiveness.

DRUG INTERACTIONS

Ciprofibrate, it may interact with blood thinners or other cholesterol-lowering medicines, increasing the risk of muscle problems or bleeding. Because of this, it is important to inform the doctor about all prescription, over-the-counter, and herbal medicines you are taking to ensure safe use.

FOOD INTERACTIONS

Food interactions occur when certain foods or drinks affect how a medicine works in the body. With Ciprofibrate, alcohol should be avoided as it may increase the risk of liver problems, and patients are usually advised to follow a healthy, low-fat diet for better results.

CONTRAINDICATIONS

Ciprofibrate, it is not recommended in severe liver or kidney disease, allergy to the drug, and usually avoided in pregnancy and breastfeeding unless prescribed by a doctor.

SIDE EFFECTS

  • Stomach pain

  • Nausea

  • Headache

  • Muscle pain

  • Weakness

  • Dizziness

  • Liver function changes (rare)

  • Muscle damage (rare)

OVER DOSE

 In the case of Ciprofibrate, it can lead to serious effects such as severe muscle pain or damage, liver toxicity, nausea, vomiting, stomach pain, and possible kidney problems. 

TOXICITY

Ciprofibrate, toxicity may cause severe muscle damage, liver injury, stomach upset, nausea, and in serious cases, kidney problems. It is important to use the medicine only in the prescribed dose to avoid toxic effects.

Image
Slide_1
CAS Number
Ciprofibrate STD - 52214-84-3 : IMP-A- 1474058-89-3 ; IMP-C- 2469279-29-4; IMP-E - 52179-28-9 ;